{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:24:06Z","timestamp":1774441446082,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["S1291010"],"award-info":[{"award-number":["S1291010"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009158","name":"Kawasaki Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009158","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018046","name":"Nippon Kayaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.lungcan.2019.10.024","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T18:11:20Z","timestamp":1572718280000},"page":"170-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells"],"prefix":"10.1016","volume":"139","author":[{"given":"Noriko","family":"Miyake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Fukazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomu","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuyuki","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Ichiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Yamatsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Naomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagio","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2019.10.024_bib0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/10937404.2016.1195323","article-title":"Mesothelioma from asbestos exposures: epidemiologic patterns and impact in the United States","volume":"19","author":"Lemen","year":"2016","journal-title":"J. Toxicol. Environ. Health B Crit. Rev."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11912-011-0172-1","article-title":"Medical treatment of mesothelioma: anything new?","volume":"13","author":"Takigawa","year":"2011","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-011-1655-3","article-title":"Review on clinical trials of targeted treatments in malignant mesothelioma","volume":"68","author":"Jakobsen","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2443.1999.00234.x","article-title":"Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system","volume":"4","author":"Oishi","year":"1999","journal-title":"Genes Cells"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0030","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","article-title":"ROR1, an embryonic protein with an emerging role in cancer biology","volume":"5","author":"Borcherding","year":"2014","journal-title":"Protein Cell"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0035","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-12-3832","article-title":"Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis","volume":"73","author":"Cui","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0040","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fonc.2012.00034","article-title":"ROR1 and ROR2 in human malignancies: potentials for targeted therapy","volume":"2","author":"Rebagay","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0050","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-13-0005","article-title":"Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2","volume":"3","author":"O\u2019Connell","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0055","doi-asserted-by":"crossref","first-page":"32864","DOI":"10.18632\/oncotarget.15860","article-title":"ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0060","first-page":"122","article-title":"ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation","volume":"3","author":"Karachaliou","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0065","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","article-title":"NKX2-1\/TITF1\/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma","volume":"21","author":"Yamaguchi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0070","doi-asserted-by":"crossref","first-page":"10060","DOI":"10.1038\/ncomms10060","article-title":"ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1","volume":"7","author":"Yamaguchi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0075","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","article-title":"Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32","volume":"98","author":"Taniguchi","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.yexcr.2016.05.008","article-title":"Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung cancer","volume":"344","author":"Ochi","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0090","doi-asserted-by":"crossref","first-page":"14863","DOI":"10.1073\/pnas.95.25.14863","article-title":"Cluster analysis and display of genome-wide expression patterns","volume":"95","author":"Eisen","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0095","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/cas.12752","article-title":"Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model","volume":"106","author":"Minami","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-2571(97)00017-4","article-title":"Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)","volume":"38","author":"Shih","year":"1998","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1158\/0008-5472.CAN-17-0883","article-title":"PTBP3-Mediated Regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast cancer","volume":"78","author":"Hou","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/dna.2018.4467","article-title":"Genes involved in the processes of cell proliferation, migration, adhesion, and tissue development as new potential markers of porcine granulosa cellular processes","volume":"38","author":"O\u017cegowska","year":"2019","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0115","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-018-0956-3","article-title":"MNAT1 is overexpressed in colorectal cancer and mediates p53 ubiquitin-degradation to promote colorectal cancer malignance","volume":"37","author":"Zhou","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2009.03.016","article-title":"Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets","volume":"67","author":"R\u00f8e","year":"2010","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2011.06.006","article-title":"Establishment of pemetrexed-resistant non-small cell lung cancer cell lines","volume":"309","author":"Zhang","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0130","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/gtc.12599","article-title":"Critical role of the Ror-family of receptor tyrosine kinases in invasion and proliferation of malignant pleural mesothelioma cells","volume":"23","author":"Saji","year":"2018","journal-title":"Genes Cells"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0135","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1038\/s41388-019-0785-7","article-title":"ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma","volume":"38","author":"Yamaguchi","year":"2019","journal-title":"Oncogene."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0140","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-019-1019-4","article-title":"Glucocorticoids promote breast cancer metastasis","volume":"567","author":"Obradovi\u0107","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0145","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0150","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1073\/pnas.1816262116","article-title":"Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0155","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/s41375-018-0113-1","article-title":"First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells","volume":"32","author":"Hojjat-Farsangi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0160","doi-asserted-by":"crossref","first-page":"e0198038","DOI":"10.1371\/journal.pone.0198038","article-title":"A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib","volume":"13","author":"Daneshmanesh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0165","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0170","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1517\/14728222.2015.1025753","article-title":"Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy","volume":"19","author":"Shabani","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0175","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0180","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2019.10.024_bib0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1042\/BJ20150329","article-title":"Structural and biochemical studies reveal UbiG\/Coq3 as a class of novel membrane-binding proteins","volume":"470","author":"Zhu","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.lungcan.2019.10.024_bib0190","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1073\/pnas.92.10.4547","article-title":"Metaxin, a gene contiguous to both thrombospondin 3 and glucocerebrosidase, is required for embryonic development in the mouse: implications for Gaucher disease","volume":"92","author":"Bornstein","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219307056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219307056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:38:59Z","timestamp":1759235939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219307056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"alternative-id":["S0169500219307056"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.10.024","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}